Remicade Bioassays

BioOutsource is the industry leader in the biological analysis of monoclonal antibodies. We have developed a range of off-the-shelf Remicade bioassays assays to support Remicade biosimilar manufacture, process development, characterisation and comparability studies. We offer industry leading Remicade comparability and Remicade characterisation services and these can be adapted for your Remicade material where required. We have extensive experience in the development, optimisation and qualification of custom cell-based bioassays to assess the myriad of functions that can be mediated by monoclonal antibodies. If you require a Remicade bioassay method that is not listed, please contact us.

The bioassay is the only analytical method that directly measures the biological activity of Remicade and therefore represents one of the most important assessments that should be conducted as part of product characterisation, lot release and stability programs. The ICH guideline Q6B – Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products describes the bioassay as:

Assessment of the biological properties constitutes an equally essential step in establishing a complete characterization profile. An important property is the biological activity that describes the specific ability or capacity of a product to achieve a defined biological effect.

As with the majority of therapeutic monoclonal antibodies, Remicade has a number of different mechanisms of action and therefore a range of bioassays are required to measure each of these mechanisms in order to fully characterise the product and demonstrate comparability with the Originator/Innovator material. BioOutsource offers the following Remicade Bioassays:

If you require a Remicade bioassay method that is not listed, please contact us.